生物医药ETF（512290）涨超2.3%，政策支持或促行业估值修复

Group 1 - The pharmaceutical and biotechnology industry is experiencing high growth in innovative drugs, with recent government support aimed at reducing internal competition and promoting innovation [1] - The National Medical Insurance Administration has indicated that the 11th batch of centralized procurement will optimize specific rules, moving away from solely considering the lowest bid [1] - The SW pharmaceutical index rose by 1.9% in the fourth week of July 2025, with notable performances in the medical services sector (+6.7%) and medical devices (+4.4%) [1] Group 2 - The CXO and upstream pharmaceutical sectors are seeing a recovery in their business environment, while the medical device sector is expected to benefit further from policy optimizations [1] - The current premium rate of the pharmaceutical sector relative to the entire A-share market stands at 88.0%, indicating a normal level [1] - The CS Bio-Medical Index, which the Biopharmaceutical ETF (512290) tracks, includes listed companies involved in biotechnology, pharmaceuticals, and medical devices, reflecting the overall performance of the biopharmaceutical sector [1]